research use only
Cat.No.E0651
|
In vitro |
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | Formula | N/A |
Storage (From the date of receipt) | 2 years -20°C liquid | |
|---|---|---|---|---|---|
| CAS No. | 8000-78-0 | -- | Storage of Stock Solutions |
|
|
| In vitro |
This compound exhibits favorable anti‑cancer potential towards gliomas of various degrees of differentiation. It induces apoptotic death in Human astrocytoma cell lines at a low concentration(0.75 µg/ml-1.5 µg/ml). |
|---|---|
| In vivo |
Garlic oil supplementation during pregnancy and lactation protects against hypertension induced by high-fat (HF) diet in adult male offspring. The beneficial effects of this compound are associated with increased renal mRNA expression and activity of Hydrogen sulfide (H2 S)-generating enzymes, increased NO bioavailability, increased plasma short chain fatty acid levels, and alterations of gut microbiota composition. This supplementation increases abundance of genus Lactobacillus, but decreases genera Turicibacter and Staphylococcus. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT00275405 | Suspended | Healthy |
Albany Medical College |
April 2006 | Phase 4 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.